Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912692083> ?p ?o ?g. }
- W2912692083 endingPage "2532" @default.
- W2912692083 startingPage "2518" @default.
- W2912692083 abstract "The opioid crisis is a significant public health issue with more than 115 people dying from opioid overdose per day in the United States. The aim of the present study was to characterize the in vitro and in vivo pharmacological effects of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN), a μ opioid receptor (MOR) ligand that may be a potential candidate for opioid use disorder treatment that produces less withdrawal signs than naltrexone. The efficacy of NAN was compared to varying efficacy ligands at the MOR, and determined at the δ opioid receptor (DOR) and κ opioid receptor (KOR). NAN was identified as a low efficacy partial agonist for G-protein activation at the MOR and DOR, but had relatively high efficacy at the KOR. In contrast to high efficacy MOR agonists, NAN did not induce MOR internalization, downregulation, or desensitization, but it antagonized agonist-induced MOR internalization and stimulation of intracellular Ca2+ release. Opioid withdrawal studies conducted using morphine-pelleted mice demonstrated that NAN precipitated significantly less withdrawal signs than naltrexone at similar doses. Furthermore, NAN failed to produce fentanyl-like discriminative stimulus effects in rats up to doses that produced dose- and time-dependent antagonism of fentanyl. Overall, these results provide converging lines of evidence that NAN functions mainly as a MOR antagonist and support further consideration of NAN as a candidate medication for opioid use disorder treatment." @default.
- W2912692083 created "2019-02-21" @default.
- W2912692083 creator A5002754414 @default.
- W2912692083 creator A5010098064 @default.
- W2912692083 creator A5012195642 @default.
- W2912692083 creator A5021314938 @default.
- W2912692083 creator A5023437507 @default.
- W2912692083 creator A5030189017 @default.
- W2912692083 creator A5054505008 @default.
- W2912692083 creator A5055631661 @default.
- W2912692083 creator A5061694164 @default.
- W2912692083 creator A5062872027 @default.
- W2912692083 creator A5065262459 @default.
- W2912692083 creator A5084533103 @default.
- W2912692083 creator A5086664284 @default.
- W2912692083 date "2019-02-13" @default.
- W2912692083 modified "2023-10-16" @default.
- W2912692083 title "Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment" @default.
- W2912692083 cites W1250794083 @default.
- W2912692083 cites W148875415 @default.
- W2912692083 cites W1492294380 @default.
- W2912692083 cites W1837577432 @default.
- W2912692083 cites W1961836052 @default.
- W2912692083 cites W1973040201 @default.
- W2912692083 cites W1973191530 @default.
- W2912692083 cites W1974030600 @default.
- W2912692083 cites W1983915881 @default.
- W2912692083 cites W1990588425 @default.
- W2912692083 cites W1992938907 @default.
- W2912692083 cites W1994835873 @default.
- W2912692083 cites W1997772366 @default.
- W2912692083 cites W2000898418 @default.
- W2912692083 cites W2003714509 @default.
- W2912692083 cites W2004189259 @default.
- W2912692083 cites W2010455608 @default.
- W2912692083 cites W2016589872 @default.
- W2912692083 cites W2018294583 @default.
- W2912692083 cites W2026440221 @default.
- W2912692083 cites W2027215444 @default.
- W2912692083 cites W2027408247 @default.
- W2912692083 cites W2029667189 @default.
- W2912692083 cites W2037871372 @default.
- W2912692083 cites W2044676961 @default.
- W2912692083 cites W2044936430 @default.
- W2912692083 cites W2049819003 @default.
- W2912692083 cites W2050456292 @default.
- W2912692083 cites W2052029379 @default.
- W2912692083 cites W2058373165 @default.
- W2912692083 cites W2060433756 @default.
- W2912692083 cites W2062106032 @default.
- W2912692083 cites W2062353519 @default.
- W2912692083 cites W2066414494 @default.
- W2912692083 cites W2070714099 @default.
- W2912692083 cites W2070753604 @default.
- W2912692083 cites W2071379530 @default.
- W2912692083 cites W2076323933 @default.
- W2912692083 cites W2083725367 @default.
- W2912692083 cites W2088639396 @default.
- W2912692083 cites W2089748306 @default.
- W2912692083 cites W2103784780 @default.
- W2912692083 cites W2108664899 @default.
- W2912692083 cites W2119349031 @default.
- W2912692083 cites W2128918211 @default.
- W2912692083 cites W2133181632 @default.
- W2912692083 cites W2133910123 @default.
- W2912692083 cites W2140257707 @default.
- W2912692083 cites W2144775933 @default.
- W2912692083 cites W2147243399 @default.
- W2912692083 cites W2150270654 @default.
- W2912692083 cites W2150981663 @default.
- W2912692083 cites W2151076845 @default.
- W2912692083 cites W2154237001 @default.
- W2912692083 cites W2164831738 @default.
- W2912692083 cites W2243000384 @default.
- W2912692083 cites W2292748019 @default.
- W2912692083 cites W2320278463 @default.
- W2912692083 cites W2425043652 @default.
- W2912692083 cites W2561135550 @default.
- W2912692083 cites W2585121519 @default.
- W2912692083 cites W2591903906 @default.
- W2912692083 cites W2604674308 @default.
- W2912692083 cites W2617279801 @default.
- W2912692083 cites W2781483269 @default.
- W2912692083 cites W2783897324 @default.
- W2912692083 cites W2791301972 @default.
- W2912692083 cites W2792861246 @default.
- W2912692083 cites W2793292948 @default.
- W2912692083 cites W2794847387 @default.
- W2912692083 cites W2808146399 @default.
- W2912692083 cites W2821679023 @default.
- W2912692083 cites W2889166182 @default.
- W2912692083 cites W2907450274 @default.
- W2912692083 doi "https://doi.org/10.1021/acschemneuro.9b00038" @default.
- W2912692083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6520168" @default.
- W2912692083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30758946" @default.
- W2912692083 hasPublicationYear "2019" @default.
- W2912692083 type Work @default.
- W2912692083 sameAs 2912692083 @default.